Bimekizumab Safety and Tolerability in Moderate to Severe Plaque Psoriasis: Pooled Analysis from Up to 4 Years of Treatment in 5 Phase 3/3b Clinical Trials. SKIN The Journal of Cutaneous Medicine, [S. l.], v. 8, n. 4, p. s404, 2024. DOI: 10.25251/skin.8.supp.404. Disponível em: https://skin.dermsquared.com/skin/article/view/2860. Acesso em: 9 apr. 2025.